Jose A. Roca, MD (Lima, Peru), Lihteh Wu, MD (San Jose, Costa Rica), Fernando Arevalo, MD (Caracas, Venezuela), Mauricio Maia, MD (São Paulo, Brazil), Maria H. Berrocal, MD (Santurce, PR), Francisco J. Rodriguez, MD (Bogota, Colombia), Michel Eid Farah, MD, PhD (São Paulo, Brazil), Fabio Bom Aggio, MD (São Paulo, Brazil)


To describe the visual and anatomic outcomes of an intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab in eyes with macular edema secondary to central retinal vein occlusion.


Multicenter retrospective case series of 18 eyes with macular edema secondary to central retinal vein occlusion treated with an intravitreal injection of either 1.25 mg or 2.5 mg of bevacizumab. Visual acuity, ophthalmoscopic, fluorescein angiographic and OCT findings were recorded at baseline and last follow-up.


After an average follow-up of 9 weeks, the baseline logMAR visual acuity improved from 1.39 to 0.95. Central macular thickness decreased from 524 μm to 261 μm. All 4 eyes with baseline rubeosis iridis and NVE had disappearance of their neovascularization following the bevacizumab injection. No ocular or systemic complications were reported.


Despite the small number of eyes and the short follow-up in this series, it appears that anintravitreal injection of bevacizumab might be a useful treatment in  this condition.